LIMASSOL, Cyprus, Sept. 25, 2020 /PRNewswire-PRWeb/ -- 2020 has been defined by the outbreak of Covid-19, which, according to many health experts, has yet to even reach its peak. To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made an investment in pharmaceutical stocks one of the most attractive options in 2020, given the substantial potential upside of rolling out the first vaccine for Covid-19.
"EuropeFX is clearly aware of this demand, having recently expanded its offering to include a basket of Pharma Stocks. The brokerage is now offering exposure to seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine," said EuropeFX CEO Keith Ioakim.
According to EuropeFX CEO Keith Ioakim, "Hundreds of thousands have died worldwide, and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical's valuation through the roof overnight."
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety. These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
EuropeFX now has on offered the seven pharmaceutical companies leading the race for a Covid-19 vaccine globally. This includes the following companies:
Gilead Sciences Inc.
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation, and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
Founded in Darmstadt, Germany, Merck & Co is active in 66 countries, and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is involved in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
Founded in the United States in 1980, Amgen has grown to be one of the world's leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation; the Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
Dynavax Technologies Corporation develops and commercializes novel vaccines.
The Company's first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer's Disease, Biogen's revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, hematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
Moderna, Inc., a clinical-stage biotechnology company, develops therapeutics and vaccines based on messenger RNA to treat infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
About EuropeFX
EuropeFX is a leader in FX, CFDs, stocks, commodities, cryptocurrencies, and more. The Company utilizes STP trade execution, offering live webinars and education sessions and an extensive lineup of tradable assets, markets, platforms, and trading options.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
SOURCE EuropeFX
Share this article